155 related articles for article (PubMed ID: 29171759)
1. Microdosing, isotopic labeling, radiotracers and metabolomics: relevance in drug discovery, development and safety.
Wotherspoon AT; Safavi-Naeini M; Banati RB
Bioanalysis; 2017 Dec; 9(23):1913-1933. PubMed ID: 29171759
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of microdosing to assess pharmacokinetic linearity in rats using liquid chromatography-tandem mass spectrometry.
Balani SK; Nagaraja NV; Qian MG; Costa AO; Daniels JS; Yang H; Shimoga PR; Wu JT; Gan LS; Lee FW; Miwa GT
Drug Metab Dispos; 2006 Mar; 34(3):384-8. PubMed ID: 16326814
[TBL] [Abstract][Full Text] [Related]
3. New ultrasensitive detection technologies and techniques for use in microdosing studies.
Lappin G; Wagner CC; Langer O; van de Merbel N
Bioanalysis; 2009 May; 1(2):357-66. PubMed ID: 21083172
[TBL] [Abstract][Full Text] [Related]
4. Isotopic labeling of metabolites in drug discovery applications.
Iglesias J; Sleno L; Volmer DA
Curr Drug Metab; 2012 Nov; 13(9):1213-25. PubMed ID: 22519368
[TBL] [Abstract][Full Text] [Related]
5. Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide.
Burt T; John CS; Ruckle JL; Vuong LT
Expert Opin Drug Deliv; 2017 May; 14(5):657-672. PubMed ID: 27564533
[TBL] [Abstract][Full Text] [Related]
6. Addressing metabolite safety during first-in-man studies using ¹⁴C-labeled drug and accelerator mass spectrometry.
Lappin G; Seymour M
Bioanalysis; 2010 Jul; 2(7):1315-24. PubMed ID: 21083242
[TBL] [Abstract][Full Text] [Related]
7. Approaches using molecular imaging technology -- use of PET in clinical microdose studies.
Wagner CC; Langer O
Adv Drug Deliv Rev; 2011 Jun; 63(7):539-46. PubMed ID: 20887762
[TBL] [Abstract][Full Text] [Related]
8. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
Lappin G; Garner RC
Nat Rev Drug Discov; 2003 Mar; 2(3):233-40. PubMed ID: 12612650
[TBL] [Abstract][Full Text] [Related]
9. Natural isotope correction of MS/MS measurements for metabolomics and (13)C fluxomics.
Niedenführ S; ten Pierick A; van Dam PT; Suarez-Mendez CA; Nöh K; Wahl SA
Biotechnol Bioeng; 2016 May; 113(5):1137-47. PubMed ID: 26479486
[TBL] [Abstract][Full Text] [Related]
10. Developing a cassette microdosing approach to enhance the throughput of PET imaging agent screening.
Xiao H; Sun M; Zhao R; Hong H; Zhang A; Zhang S; Liu F; Zhang Y; Liu Y; Zhu L; Kung HF; Qiao J
J Pharm Biomed Anal; 2018 May; 154():48-56. PubMed ID: 29533858
[TBL] [Abstract][Full Text] [Related]
11. Radiotracer development in psychiatry.
Pimlott SL
Nucl Med Commun; 2005 Mar; 26(3):183-8. PubMed ID: 15722898
[TBL] [Abstract][Full Text] [Related]
12. Identifying novel radiotracers for PET imaging of the brain: application of LC-MS/MS to tracer identification.
Barth V; Need A
ACS Chem Neurosci; 2014 Dec; 5(12):1148-53. PubMed ID: 24828747
[TBL] [Abstract][Full Text] [Related]
13. Applications of LC-MS in PET radioligand development and metabolic elucidation.
Ma Y; Kiesewetter DO; Lang L; Gu D; Chen X
Curr Drug Metab; 2010 Jul; 11(6):483-93. PubMed ID: 20540692
[TBL] [Abstract][Full Text] [Related]
14. Experiments for a systematic comparison between stable-isotope-(deuterium) labeling and radio-((14)C) labeling for the elucidation of the in vitro metabolic pattern of pharmaceutical drugs.
Grunwald H; Hargreaves P; Gebhardt K; Klauer D; Serafyn A; Schmitt-Hoffmann A; Schleimer M; Schlotterbeck G; Wind M
J Pharm Biomed Anal; 2013 Nov; 85():138-44. PubMed ID: 23933567
[TBL] [Abstract][Full Text] [Related]
15. Microdosing studies in humans: the role of positron emission tomography.
Bauer M; Wagner CC; Langer O
Drugs R D; 2008; 9(2):73-81. PubMed ID: 18298126
[TBL] [Abstract][Full Text] [Related]
16. Post-acquisition data mining techniques for LC-MS/MS-acquired data in drug metabolite identification.
Dhurjad PS; Marothu VK; Rathod R
Bioanalysis; 2017 Aug; 9(16):1265-1278. PubMed ID: 28816067
[TBL] [Abstract][Full Text] [Related]
17. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
Nassar AE; Talaat RE; Kamel AM
Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
[TBL] [Abstract][Full Text] [Related]
18. Development of radiodetection systems towards miniaturised quality control of PET and SPECT radiopharmaceuticals.
Taggart MP; Tarn MD; Esfahani MM; Schofield DM; Brown NJ; Archibald SJ; Deakin T; Pamme N; Thompson LF
Lab Chip; 2016 Apr; 16(9):1605-16. PubMed ID: 27044712
[TBL] [Abstract][Full Text] [Related]
19. Development of isotope labeling liquid chromatography mass spectrometry for mouse urine metabolomics: quantitative metabolomic study of transgenic mice related to Alzheimer's disease.
Peng J; Guo K; Xia J; Zhou J; Yang J; Westaway D; Wishart DS; Li L
J Proteome Res; 2014 Oct; 13(10):4457-69. PubMed ID: 25164377
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
